Randomized control trial of Abiraterone and Enzalutamide for castration resistant prostate cancer patients.
Not Applicable
Recruiting
- Conditions
- Castration resistant prostate cancer
- Registration Number
- JPRN-UMIN000022102
- Lead Sponsor
- Department of Urology Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Not specifically defined.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA response rate in each group of abiraterone and enzalutamide as primary therapy
- Secondary Outcome Measures
Name Time Method 1. PSA or radiographic progression free rate in each group of abiraterone and enzalutamide as primary therapy 2. PSA response rate in each group of abiraterone and enzalutamide as primary therapy 3. PSA or radiographic progression free rate in each group of abiraterone and enzalutamide as whole therapy after cross-over 4. Time until introduction of chemotherapy or best supportive care (BSC) 5. Overall survival time 6. QOL analysis by FACT P 7. Adverse events in each group of abiraterone and enzalutamide